Counts of patients and donors in the GVHD and non-GVHD groups
| Variable . | Acute GVHD . | No acute GVHD . | P . |
|---|---|---|---|
| Number of recipients | 102 | 103 | |
| Number of centers | 47 | 50 | |
| Patient related | |||
| Recipient age at transplant, y | .09 | ||
| 0-9 | 3 (3) | 1 (1) | |
| 10-19 | 10 (10) | 6 (6) | |
| 20-29 | 16 (16) | 17 (17) | |
| 30-39 | 21 (21) | 15 (15) | |
| 40-49 | 23 (23) | 42 (41) | |
| 50-59 | 29 (28) | 22 (21) | |
| Median (range) | 41 (1-66) | 44 (9-66) | .58 |
| Recipient race/ethnicity | .79 | ||
| White, non-Hispanic | 87 (92) | 94 (92) | |
| African American, non-Hispanic | 1 (1) | 2 (2) | |
| Asian, non-Hispanic | 2 (2) | 3 (3) | |
| Hispanic, white | 5 (5) | 3 (3) | |
| Unknown | 7 (N/A) | 1 (N/A) | |
| Recipient sex | .009 | ||
| Male | 64 (63) | 46 (45) | |
| Female | 38 (37) | 57 (55) | |
| Karnofsky score | .47 | ||
| 10-80 | 24 (24) | 32 (31) | |
| 90-100 | 72 (71) | 66 (64) | |
| Missing | 6 (6) | 5 (5) | |
| Disease related | |||
| Disease status at transplant | .61 | ||
| Early (CR1) | 71 (70) | 75 (73) | |
| Intermediate (CR2+) | 31 (30) | 28 (27) | |
| Transplant related | |||
| Stem cell source | .24 | ||
| Marrow | 27 (26) | 35 (34) | |
| PBSCs | 75 (74) | 68 (66) | |
| TCE nonpermissiveness | .22 | ||
| Ambiguous DPB1 allele | 0 | 1 (1) | |
| Permissive DPB1 | 54 (54) | 62 (63) | |
| Nonpermissive DPB1 | 46 (46) | 35 (36) | |
| Data missing | 2 (N/A) | 5 (N/A) | |
| GVHD prophylaxis | .80 | ||
| Tacrolimus + MMF ± others | 22 (22) | 20 (19) | |
| Tacrolimus + MTX ± others (except MMF) | 56 (55) | 57 (55) | |
| Tacrolimus + others (except MTX, MMF) | 5 (5) | 2 (2) | |
| Tacrolimus alone | 3 (3) | 1 (1) | |
| CSA + MMF ± others (except tacrolimus) | 2 (2) | 3 (3) | |
| CSA + MTX ± others (except tacrolimus, MMF) | 12 (12) | 18 (17) | |
| CSA + others (except tacrolimus, MTX, MMF) | 1 (1) | 1 (1) | |
| CSA alone | 1 (1) | 1 (1) | |
| Donor–recipient sex matching | .007 | ||
| Male–male | 44 (42) | 40 (39) | |
| Male–female | 24 (25) | 38 (37) | |
| Female–male | 21 (21) | 6 (6) | |
| Female–female | 13 (13) | 19 (18) | |
| Donor–recipient CMV serostatus | .68 | ||
| Negative–negative | 33 (32) | 29 (28) | |
| Negative–positive | 37 (36) | 36 (35) | |
| Positive–negative | 10 (10) | 14 (14) | |
| Positive–positive | 19 (19) | 23 (22) | |
| Unknown | 3 (3) | 1 (1) | |
| Donor age at donation, y | .18 | ||
| 18-19 | 4 (4) | 1 (1) | |
| 20-29 | 45 (44) | 54 (52) | |
| 30-39 | 29 (28) | 31 (30) | |
| 40-49 | 16 (16) | 15 (15) | |
| ≥50 | 8 (8) | 2 (2) | |
| Median (range) | 30 (19-56) | 28 (20-52) | .11 |
| Donor–recipient ethnicity matching | |||
| African American–African American | 0 (0) | 2 (2) | |
| Asian-Pacific Islander–Asian-Pacific Islander | 2 (2) | 2 (2) | |
| Asian-Pacific Islander–white | 0 (0) | 2 (2) | |
| White–African American | 2 (2) | 1 (1) | |
| White–white | 84 (82) | 85 (83) | |
| White–deceased | 3 (3) | 2 (2) | |
| White–Native American | 0 (0) | 2 (2) | |
| White–unknown | 4 (4) | 2 (2) | |
| Hispanic–white | 1 (1) | 2 (2) | |
| Hispanic–deceased | 1 (1) | 0 (0) | |
| Hispanic–unknown | 1 (1) | 1 (1) | |
| Multiple–white | 3 (3) | 1 (1) | |
| Unknown–white | 1 (1) | 1 (1) | |
| Year of transplant | .61 | ||
| 2000 | 0 | 3 (3) | |
| 2001 | 2 (2) | 4 (4) | |
| 2002 | 1 (1) | 0 | |
| 2003 | 1 (1) | 3 (3) | |
| 2004 | 5 (5) | 8 (8) | |
| 2005 | 15 (15) | 11 (11) | |
| 2006 | 16 (16) | 15 (15) | |
| 2007 | 17 (17) | 17 (17) | |
| 2008 | 11 (11) | 8 (8) | |
| 2009 | 14 (14) | 9 (9) | |
| 2010 | 18 (18) | 22 (21) | |
| 2011 | 2 (2) | 3 (3) | |
| Follow-up among survivors, mo | |||
| Number evaluated | 44 | 50 | |
| Median (range) | 60 (33-99) | 61 (30-123) | .93 |
| Variable . | Acute GVHD . | No acute GVHD . | P . |
|---|---|---|---|
| Number of recipients | 102 | 103 | |
| Number of centers | 47 | 50 | |
| Patient related | |||
| Recipient age at transplant, y | .09 | ||
| 0-9 | 3 (3) | 1 (1) | |
| 10-19 | 10 (10) | 6 (6) | |
| 20-29 | 16 (16) | 17 (17) | |
| 30-39 | 21 (21) | 15 (15) | |
| 40-49 | 23 (23) | 42 (41) | |
| 50-59 | 29 (28) | 22 (21) | |
| Median (range) | 41 (1-66) | 44 (9-66) | .58 |
| Recipient race/ethnicity | .79 | ||
| White, non-Hispanic | 87 (92) | 94 (92) | |
| African American, non-Hispanic | 1 (1) | 2 (2) | |
| Asian, non-Hispanic | 2 (2) | 3 (3) | |
| Hispanic, white | 5 (5) | 3 (3) | |
| Unknown | 7 (N/A) | 1 (N/A) | |
| Recipient sex | .009 | ||
| Male | 64 (63) | 46 (45) | |
| Female | 38 (37) | 57 (55) | |
| Karnofsky score | .47 | ||
| 10-80 | 24 (24) | 32 (31) | |
| 90-100 | 72 (71) | 66 (64) | |
| Missing | 6 (6) | 5 (5) | |
| Disease related | |||
| Disease status at transplant | .61 | ||
| Early (CR1) | 71 (70) | 75 (73) | |
| Intermediate (CR2+) | 31 (30) | 28 (27) | |
| Transplant related | |||
| Stem cell source | .24 | ||
| Marrow | 27 (26) | 35 (34) | |
| PBSCs | 75 (74) | 68 (66) | |
| TCE nonpermissiveness | .22 | ||
| Ambiguous DPB1 allele | 0 | 1 (1) | |
| Permissive DPB1 | 54 (54) | 62 (63) | |
| Nonpermissive DPB1 | 46 (46) | 35 (36) | |
| Data missing | 2 (N/A) | 5 (N/A) | |
| GVHD prophylaxis | .80 | ||
| Tacrolimus + MMF ± others | 22 (22) | 20 (19) | |
| Tacrolimus + MTX ± others (except MMF) | 56 (55) | 57 (55) | |
| Tacrolimus + others (except MTX, MMF) | 5 (5) | 2 (2) | |
| Tacrolimus alone | 3 (3) | 1 (1) | |
| CSA + MMF ± others (except tacrolimus) | 2 (2) | 3 (3) | |
| CSA + MTX ± others (except tacrolimus, MMF) | 12 (12) | 18 (17) | |
| CSA + others (except tacrolimus, MTX, MMF) | 1 (1) | 1 (1) | |
| CSA alone | 1 (1) | 1 (1) | |
| Donor–recipient sex matching | .007 | ||
| Male–male | 44 (42) | 40 (39) | |
| Male–female | 24 (25) | 38 (37) | |
| Female–male | 21 (21) | 6 (6) | |
| Female–female | 13 (13) | 19 (18) | |
| Donor–recipient CMV serostatus | .68 | ||
| Negative–negative | 33 (32) | 29 (28) | |
| Negative–positive | 37 (36) | 36 (35) | |
| Positive–negative | 10 (10) | 14 (14) | |
| Positive–positive | 19 (19) | 23 (22) | |
| Unknown | 3 (3) | 1 (1) | |
| Donor age at donation, y | .18 | ||
| 18-19 | 4 (4) | 1 (1) | |
| 20-29 | 45 (44) | 54 (52) | |
| 30-39 | 29 (28) | 31 (30) | |
| 40-49 | 16 (16) | 15 (15) | |
| ≥50 | 8 (8) | 2 (2) | |
| Median (range) | 30 (19-56) | 28 (20-52) | .11 |
| Donor–recipient ethnicity matching | |||
| African American–African American | 0 (0) | 2 (2) | |
| Asian-Pacific Islander–Asian-Pacific Islander | 2 (2) | 2 (2) | |
| Asian-Pacific Islander–white | 0 (0) | 2 (2) | |
| White–African American | 2 (2) | 1 (1) | |
| White–white | 84 (82) | 85 (83) | |
| White–deceased | 3 (3) | 2 (2) | |
| White–Native American | 0 (0) | 2 (2) | |
| White–unknown | 4 (4) | 2 (2) | |
| Hispanic–white | 1 (1) | 2 (2) | |
| Hispanic–deceased | 1 (1) | 0 (0) | |
| Hispanic–unknown | 1 (1) | 1 (1) | |
| Multiple–white | 3 (3) | 1 (1) | |
| Unknown–white | 1 (1) | 1 (1) | |
| Year of transplant | .61 | ||
| 2000 | 0 | 3 (3) | |
| 2001 | 2 (2) | 4 (4) | |
| 2002 | 1 (1) | 0 | |
| 2003 | 1 (1) | 3 (3) | |
| 2004 | 5 (5) | 8 (8) | |
| 2005 | 15 (15) | 11 (11) | |
| 2006 | 16 (16) | 15 (15) | |
| 2007 | 17 (17) | 17 (17) | |
| 2008 | 11 (11) | 8 (8) | |
| 2009 | 14 (14) | 9 (9) | |
| 2010 | 18 (18) | 22 (21) | |
| 2011 | 2 (2) | 3 (3) | |
| Follow-up among survivors, mo | |||
| Number evaluated | 44 | 50 | |
| Median (range) | 60 (33-99) | 61 (30-123) | .93 |
Data are expressed as n (%), except as noted. P values were calculated using the Pearson χ2 test to compare discrete variables or the Kruskal-Wallis test to compare continuous variables.
CMV, cytomegalovirus; CSA, cyclosporine; MMF, mycophenolate mofetil; MTX, methotrexate; PBSCs, peripheral blood stem cells.